Press Release

CREATIVE DIAGNOSTICS ANNOUNCES NEW CLDN6 SOLUTIONS FOR CANCER RESEARCH



Creative Diagnostics has launched a range of antibodies, antigens and kits against CLDN6 to support researchers.

FOR IMMEDIATE RELEASE

03/11/2023

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has launched a range of antibodies, antigens and kits against CLDN6 to support researchers worldwide in preclinical and clinical safety/efficacy testing. CLDN6 may be involved in the development and progression of many malignancies, including breast cancer, gastric cancer and hepatocellular carcinoma (HCC).

Several members of the claudin (CLDN) family are located at tight junctions between epithelial cells, and aberrant expression of CLDN6 may play multiple roles in tumorigenesis and progression. It encodes a tetratransmembrane protein of 220 amino acids with a molecular mass of 23,292 Da. CLDN6 has been identified as the origin of cell adhesion signaling and is involved in the regulation of nuclear receptor activity by targeting nuclear receptor superfamily molecules and managing their gene expression.

As a member of the claudin family, CLDN6 is considered a "new favorite" for targeted cancer therapy after CLDN18. Based on the spatial structure and regulatory properties of CLDN6, the exploration or design of CLDN6-targeted drugs to positively regulate CLDN6-related signaling molecules and interfere with tumor progression is of great value for early diagnosis and precision treatment of tumors.

CLDN6 expression is associated with prognosis in patients with a variety of tumors. It is currently being investigated for use in novel immunotherapies for the treatment of cancer, including monoclonal antibodies, bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy. For instance, the use of CLDN6 antibodies can block tumor growth and prolong the lives of TGCT patients. The presence of tumor-associated antigens induces a potent and long-lasting antigen-specific T-cell response, breaking the immune system's tolerance to endogenous autoantigens and producing an effective anti-tumor effect.

T cell-engaging bispecific antibodies (TCEs) are potent tumor targeting agents that enhance recognition by binding a patient's T cells to proteins expressed on the surface of cancer cells, enabling the T cells to kill the cancer cells. 6PHU3, a T cell-inducing single-chain bispecific molecule with anti-CD3/anti-CLDN6 specificity (bi-(scFv)2), has been shown to be effective in the treatment of CLDN6-positive solid tumors with high specificity and efficiency.

Creative Diagnostics now offers a range of antibodies, antigens and kits against CLDN6 to support customers worldwide in their preclinical and clinical safety/efficacy testing. For example, the Claudin 6 (Phospho-Tyr219) ELISA Kit (Catalog # DEIA-XYA431) is a convenient, lysate-free, high-throughput and highly sensitive assay for monitoring the phosphorylation and expression profile of Claudin 6 protein in cells. The kit can be used to measure the relative amount of phosphorylated Claudin 6 in cultured cells as well as to screen for the effects of various treatments, inhibitors (i.e., siRNAs or chemical reagents) or activators on Claudin 6 phosphorylation.

To learn more information about the products for CLDN6 and Cancer, please visit https://www.creative-diagnostics.com/cldn6-an-emerging-role-in-cancer.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Tags:
CLDN6 Solutions  |  Creative Diagnostics  |  

---

Organisation Profile:
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.






Press release contact details for Creative Diagnostics

NameCreative Diagnostics
Tel
Fax
Email
Websitehttps://www.creative-diagnostics.com/
OrganisationCreative Diagnostics
Address
Town
County0
Postcode11967




Other press releases from Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing Read more: https://www.digitaljournal.com/pr/news/getnews/creative-diagnostics-announces-new-mbc-assay-for-antibacterial-testing#ixzz8KcL65cji
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics Launches New P53 and TP53 Antibodies for Cancer Research
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Citrinin Test Reagents for Food Safety
Creative Diagnostics Announces Novel Agar Gel Precipitin Tests for Viral Antigen Detection
Creative Diagnostics Introduces Cutting-Edge Anti-AAV Antibody ELISA Kits for Gene Therapy Research
Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection
Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development
Creative Diagnostics Announces Comprehensive Vomitoxin Test Reagents for Food Safety Applications
High-Affinity Anti Venom Antibodies for Research Applications
Creative Diagnostics Introduces Immunofluorescence Assay Testing Services for Virology Research
Creative Diagnostics Launches Comprehensive Fumonisin Test Reagents for Precise Food Safety Analysis
Creative Diagnostics Introduces Comprehensive Range of Ochratoxin Test Reagents for Enhanced Food Safety Analysis
Creative Diagnostics Launches Plaque Reduction Assay Services to Advance Antiviral Research
Creative Diagnostics Announces the Launch of Norovirus VLP Antigens to Support Vaccine Research
Creative Diagnostics Introduces Patulin Test Reagents for Food Safety Applications
Creative Diagnostics Launches Reliable Hemagglutination Assay for Virus and Antibody Detection
Creative Diagnostics Announces High-Affinity Anti-Adenovirus Monoclonal Antibodies for Research and Assay Development

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.